| 牟伦盼 蒋建家 林振忠 苏劲波 孙炳庆 庄玉君 明德松.艾塞那肽在非糖尿病肥胖人群中应用的安全性[J].实用中西医结合临床,2014,14(2):3-5 |
| 艾塞那肽在非糖尿病肥胖人群中应用的安全性 |
| The Safety of Exenatide Administered in Non-diabetic Obese Population |
| |
| DOI： |
| 中文关键词: 艾塞那肽 肥胖 低血糖 不良事件 |
| 英文关键词: Exenatide Obesity Hypoglycemia Adverse event |
| 基金项目:福建省泉州市科技计划项目（基金编号：2010Z21） |
|
| 摘要点击次数: 630 |
| 全文下载次数: 352 |
| 中文摘要: |
| 目的：探讨艾塞那肽在非糖尿病肥胖受试者中应用的安全性。方法：以非糖尿病肥胖自愿者为研究对象，年龄>18岁，体质指数（BMI）>25 kg/m2，腰围男>90 cm，女>85 cm。测定基线及应用艾塞那肽7 d后的空腹与早餐后2 h血浆血糖，行72 h动态血糖监测，每日8点指尖血糖监测。结果：29例受试者均完成临床观察。基线与艾塞那肽应用后，空腹血糖为（5.2±0.3） mmol/L与（4.7±0.3） mmol/L（P<0.01），早餐后2 h血糖为（6.2±1.1） mmol/L与（5.9±1.0） mmol/L（P>0.05），体重为（80.6±7.6） kg与（79.5±7.7） kg（P<0.01）；72 h连续动态血糖监测血糖低值 3.1 mmol/L，血糖高值8.7 mmol/L。最常见不良事件为轻度或中度消化道症状，其中9例出现恶心、3例呕吐、2例腹胀，另有3例头晕，无严重低血糖事件发生。结论：艾塞那肽短期应用于非糖尿病肥胖人群低血糖风险小，主要不良事件为轻中度消化道症状。 |
| 英文摘要: |
| Objective: To investigate the initial safety of exenatide administered in Non-diabetic obese population. Methods: Non-diabetic obese volunteers, >18 years old, BMI>25 kg/m2, waistline (male>90 cm and female>85 cm). Baseline and 7 days after application of exenatide, fasting plasma glucose, 2 h postprandial plasma glucose, and 72 h dynamic blood glucose were measured. Results: 29 Cases completed the clinical observation. Baseline and after application of exenatide, the fasting plasma glucose were (5.2±0.3) mmol/L and (4.7±0.3) mmol/L (P<0.01). The 2 h plasma glucose were (6.2±1.1) mmol/L and (5.9±1.0) mmol/L (P>0.05). The body weight were (80.6±7.6) kg and (79.5±7.7) kg (P<0.01). The 72 h dynamic blood glucose monitoring shows the low-value was 3.1 mmol/L and the high-value was 8.7 mmol/L. The most frequent adverse events was mild or moderate alimentary symptoms, nausea 9 cases, vomiting 3 cases and abdominal distension 2 cases. Other adverse event was dizziness (3 cases). No hypoglycemia event. Conclusions: Exenatide short-term applied to non-diabetic obese population hasn’t the risk of hypoglycemia, mild to moderate alimentary symptoms is the main adverse events. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
